New drugs blast budgets. Patients benefit; hospital pharmacies weigh options.
Hensley
S
S
D000077284:Abciximab; D000787:Angina Pectoris / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000191:economics; D000925:Anticoagulants / Q000191:economics*; D017277:Drug Approval; D016527:Drug Costs / Q000639:trends*; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics; D010455:Peptides / Q000191:economics; D010607:Pharmacy Service, Hospital / Q000191:economics*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab